{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:07:08Z","timestamp":1792534028807,"version":"4.5.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Castration-resistant prostate cancer (CRPC) remains a difficult clinical problem, although androgen deprivation therapy and next-generation androgen receptor (AR) pathway inhibitors have greatly improved patient treatment. CRPC is not simply an androgen-independent disease. In many cases, tumor cells still depend on persistent or restored AR signaling under castrate conditions. AR reactivation is driven by several overlapping mechanisms, including AR amplification, AR overexpression, ligand-binding domain mutations, AR splice variants, intratumoral androgen synthesis, bypass signaling, and altered AR co-regulators. The AR axis is also connected with DNA damage repair. For example, PARP-1 can support both DNA repair and AR-driven transcription, which provides a rationale for combining AR-targeted therapy with PARP inhibition in selected patients. Epigenetic adaptation is another key layer in this process. Changes in chromatin accessibility, AR cistrome redistribution, pioneer factors, enhancer activity, and chromatin-modifying cofactors can reshape AR-dependent transcription. These changes help tumor cells maintain AR signaling and also promote heterogeneity, lineage plasticity, and more aggressive phenotypes. Recent single-cell transcriptomic and epigenomic studies further show that CRPC contains diverse resistant cell states, which may change during treatment. Importantly, these resistance mechanisms may also create therapeutic opportunities. Current and emerging strategies include AR degraders, AR N-terminal domain inhibitors, inhibitors of steroidogenesis and bypass pathways, PARP inhibitors, and epigenetic therapies targeting EZH2, BET proteins, p300\/CBP, LSD1, or HDACs. Biomarker-guided treatment, including AR variants, DNA repair defects, ctDNA profiles, and chromatin states, may help select better therapies for CRPC patients.<\/jats:p>","DOI":"10.3389\/fonc.2026.1837998","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:39:25Z","timestamp":1779338365000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities"],"prefix":"10.3389","volume":"16","author":[{"given":"Juntao","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Urology, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Urology, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/bs.acr.2024.05.007","article-title":"Epigenetic regulation of androgen dependent and independent prostate cancer","volume":"161","author":"Mishra","year":"2024","journal-title":"Adv Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1769271","article-title":"Characteristics and therapeutic resistance mechanisms of the prostate cancer immune microenvironment: a comprehensive analysis from bench to clinic","volume":"17","author":"Li","year":"2026","journal-title":"Front Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.115","article-title":"Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects","volume":"34","author":"Ferraldeschi","year":"2015","journal-title":"Oncogene"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3447","article-title":"Shaping chromatin states in prostate cancer by pioneer transcription factors","volume":"80","author":"Hankey","year":"2020","journal-title":"Cancer Res"},{"key":"B8","article-title":"Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer","volume":"57","author":"Koivisto","year":"1997","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-9896(199912)189:4<559::aid-path471>3.0.co;2-y","article-title":"Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer","volume":"61","author":"Linja","year":"2001","journal-title":"Cancer Res"},{"key":"B10","article-title":"Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen","volume":"61","author":"Gregory","year":"2001","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/138920209787581307","article-title":"The role of androgen receptor mutations in prostate cancer progression","volume":"10","author":"Brooke","year":"2009","journal-title":"Curr Genomics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019059","article-title":"Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival","volume":"6","author":"H\u00f6rnberg","year":"2011","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0172-0","article-title":"Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases","volume":"119","author":"Kallio","year":"2018","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2018.1427068","article-title":"CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer","volume":"18","author":"Bastos","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0532","article-title":"Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.235","article-title":"Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis","volume":"33","author":"Yuan","year":"2014","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.7310","article-title":"Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.152789","article-title":"Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer","volume":"6","author":"De Sarkar","year":"2021","journal-title":"JCI Insight"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-1720","article-title":"MECOM function is critical for AR-driven treatment-resistant prostate cancer","volume":"86","author":"Gulla","year":"2026","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.01.009","article-title":"Epigenetic reprogramming during prostate cancer progression: a perspective from development","volume":"83","author":"Goel","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1083486","article-title":"The epigenetic function of androgen receptor in prostate cancer progression","volume":"11","author":"Sawada","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.496","article-title":"FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression","volume":"35","author":"Zhao","year":"2016","journal-title":"Oncogene"},{"key":"B32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13238-020-00786-8","article-title":"Pioneer of prostate cancer: past, present and the future of FOXA1","volume":"12","author":"Teng","year":"2021","journal-title":"Protein Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1718811115","article-title":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","volume":"115","author":"Chen","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.27861","article-title":"Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer","volume":"6","author":"Shah","year":"2017","journal-title":"Elife"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002038","article-title":"Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC","volume":"21","author":"Schade","year":"2023","journal-title":"PloS Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03148-4","article-title":"AR coactivators, CBP\/p300, are critical mediators of DNA repair in prostate cancer","volume":"43","author":"Sardar","year":"2024","journal-title":"Oncogene"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn0478","article-title":"Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling","volume":"377","author":"Chan","year":"2022","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1038\/s41467-021-25624-1","article-title":"Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse","volume":"12","author":"Taavitsainen","year":"2021","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.stem.2024.05.008","article-title":"Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells","volume":"31","author":"Kirk","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322203121","article-title":"Single-cell analysis of treatment-resistant prostate cancer: implications of cell state changes for cell surface antigen-targeted therapies","volume":"121","author":"Zaidi","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1924","article-title":"Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell-cycle-related transcription and attenuated androgen response","volume":"78","author":"Horning","year":"2018","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s42003-020-01476-1","article-title":"Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer","volume":"3","author":"Dong","year":"2020","journal-title":"Commun Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.03.530998","article-title":"Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells","volume":"31","author":"Kirk","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000254","article-title":"Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer","volume":"23","author":"Teply","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clgc.2019.09.015","article-title":"Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer","volume":"18","author":"Zhang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0422","article-title":"Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence","volume":"23","author":"Coutinho","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of Bavdegalutamide (ARV-110), a novel PROteolysis TArgeting Chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66398","article-title":"An androgen receptor N-terminal domain antagonist for treating prostate cancer","volume":"123","author":"Myung","year":"2013","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2901","article-title":"Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer","volume":"22","author":"Yang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0161","article-title":"Targeting the N-terminal domain of the androgen receptor: a new approach for the treatment of advanced prostate cancer","volume":"21","author":"Antonarakis","year":"2016","journal-title":"Oncologist"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12770","article-title":"Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer","volume":"14","author":"Hirayama","year":"2020","journal-title":"Mol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz244.065","article-title":"EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer","volume":"30","author":"Moigne","year":"2019","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JCO.2020.38.6_suppl.142","article-title":"IND candidate EPI-7386 as an N-terminal domain androgen receptor inhibitor in development for the treatment of prostate cancer","volume":"38","author":"Le Moigne","year":"2020","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1451957","article-title":"N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24118","article-title":"Targeting backdoor androgen synthesis through AKR1C3 inhibition: a presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer","volume":"81","author":"Graham","year":"2021","journal-title":"Prostate"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4049","article-title":"Phase I\/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer","volume":"28","author":"Serritella","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3636","article-title":"A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration-resistant prostate cancer","volume":"30","author":"Desai","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.21037\/tau-22-501","article-title":"A narrative review of the role of glucocorticoid receptors in prostate cancer: developments in last 5 years","volume":"11","author":"Zhou","year":"2022","journal-title":"Transl Androl Urol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115200","article-title":"Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer","volume":"404","author":"Shankar","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1075707","article-title":"Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer","volume":"11","author":"Sreekumar","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B68","unstructured":"clinicaltrials.gov Arvinas Inc\n          A Phase 1\/2, Open-label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer\n          \n          2025"},{"key":"B69","doi-asserted-by":"publisher","first-page":"S990","DOI":"10.1016\/j.annonc.2024.08.1722","article-title":"1641P Phase I\/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects","volume":"35","author":"Kyriakopoulos","year":"2024","journal-title":"Ann Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01202-6","article-title":"A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer","volume":"40","author":"Maurice-Dror","year":"2022","journal-title":"Invest New Drugs"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1021\/jm3017656","article-title":"Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase) in castrate-resistant prostate cancer","volume":"56","author":"Liedtke","year":"2013","journal-title":"J Med Chem"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS288","article-title":"Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: the phase 3, randomized MEVPRO-1 study","volume":"43","author":"Agarwal","year":"2025","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A phase Ib\/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131041","article-title":"Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer","volume":"130","author":"Beltran","year":"2020","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1837998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:39:46Z","timestamp":1779338386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1837998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":76,"alternative-id":["10.3389\/fonc.2026.1837998"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1837998","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1837998"}}